Stock of the Day

Aptose Biosciences (APTO)

$0.16

-$0.03 (-14.7%)

Market Cap: $12.22M

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Recent News

• Aptose Biosciences approved to escalate dose in Phase 1/2 AML trial (markets.businessinsider.com)
• Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort (globenewswire.com)
• Aptose Biosciences, Inc.: Aptose Announces Reverse Share Split (finanznachrichten.de)
• Aptose Biosciences announces 1-for-30 reverse share split (markets.businessinsider.com)
• Aptose Announces Reverse Share Split (globenewswire.com)